Skip to main content

Specialty Pharmacy

  • Silvergate Pharmaceuticals announces Xatmep availability

    DENVER — The first methotrexate oral solution approved by the Food and Drug Administration, Xatmep, is now available, manufacturer Silvergate Pharmaceuticals announced Monday. The drug, approved by the FDA in April, is indicated to treat acute lymphoblastic leukemia and manage polyarticular juvenile idiopathic arthritis in pediatric patients.

  • Former Lilly USA president to keynote National Association of Specialty Pharmacy conference

    WASHINGTON — Pharmaceutical executive, healthcare industry leader and former president of Lilly USA, Alex Azar, will kick off the fifth annual National Association of Specialty Pharmacy conference with a keynote speech on Sept. 19 in Washington, D.C.

  • Breast cancer, hepatitis C drugs get FDA approval
    SILVER SPRING, Md. — The Food and Drug Administration this week has approved two new drugs, Gilead’s hepatitis C treatment Vosevi and Puma Biotechnology’s breast cancer drug Nerlynx. 
     

  • NASP adds Walgreens, Pfizer and AstraZeneca execs to board
    WASHINGTON — The National Association of Specialty Pharmacy has added three new members to its board of directors. The organization brought on Walgreens VP federal government relations and U.S. public policy Ed Kaleta; Pfizer's regional president North America for rare disease Tolga Tangular; and AstraZeneca’s executive director of access services Blaine Squires. 
     

  • FDA approves Janssen’s plaque psoriasis drug Tremfya

    SILVER SPRING, Md. — The Food and Drug Adminisration has approved Janssen Biotech’s new treatment for plaque psoriasis, the company announced Thursday. Tremfya (guselkumab) is the first drug to be approved that selectively blocks a key plaque psoriasis cytokine, the company said.

  • PhRMA adds 2 VPs
    WASHINGTON — The Pharmaceutical Research and Manufacturers of America this week announced two new additions to its ranks. The company has added Mike Hotra as VP of its public affairs team, and Ken McKay as VP state government affairs. 
     

  • FDA grants full approval to Amgen’s Blincyto

    SILVER SPRING, Md. — Patients with a certain type of acute lymphoblastic leukemia have a new treatment option. The Food and Drug Administration has granted Amgen’s Blincyto (blinatumomab) full approval for the treatment of Philadelphia Chromosome-positive relaped or refractory B-cell precursor ALL.

  • Diplomat’s ThriveRx celebrates 10 years with new platforms

    CINCINNATI  — Diplomat Specialty Infusion Group’s nutrition division ThriveRx is celebrating 10 years of supporting parenteral and enteral nutrition patients with a website redesign and the rebrand of its Maximize Health program. The redesigned thriverx.diplomat.is features a new look with improved organization in an effort to improve the patient and health care professional experience on the site.

X
This ad will auto-close in 10 seconds